rawfin.tv
AbbVie Drug Atogepant Reduces Menstrual Migraine Days in Phase 3 Trial
MarketsstocksAI Generated

AbbVie Drug Atogepant Reduces Menstrual Migraine Days in Phase 3 Trial

By rawfin.tv Markets Desk||1 min read|AI-assisted · Methodology

AbbVie announced positive topline results from its Phase 3 LUNA clinical trial, demonstrating that its drug atogepant significantly reduced menstrual migraine days. These findings could pave the way for a new treatment option and boost AbbVie's pharmaceutical portfolio.

ABBVPharmaceuticalsClinical TrialsDrug Development

Related Articles

Adidas Surges 37% to Record Q3 Profit, Lifts Full-Year Targets

Adidas Surges 37% to Record Q3 Profit, Lifts Full-Year Targets

stocks
EQT to Acquire Cleanaway Waste for $6.5 Billion

EQT to Acquire Cleanaway Waste for $6.5 Billion

stocks
S&P 500 Breaches Key Support as AI Sell-Off Pressures Tech Sector

S&P 500 Breaches Key Support as AI Sell-Off Pressures Tech Sector

stocks
US Chip Stocks Plunge 16% in Longest Losing Streak Since 2008

US Chip Stocks Plunge 16% in Longest Losing Streak Since 2008

stocks